12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Faslodex fulvestrant: Phase III started

AstraZeneca began the double-blind, placebo-controlled, international Phase III FALCON trial to compare 500 mg intramuscular Faslodex on days 0, 14 and 28 followed by every 28 days thereafter vs. 1 mg oral Arimidex anastrozole once...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >